Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colquhounia root tablet (CRT) is a traditional Chinese patent medicine prepared from the peeled root of Tripterygium hypoglaucum. It has been used for decades in China to treat autoimmune and inflammatory diseases, particularly chronic glomerulopathy and diabetic kidney disease. CRT exhibits anti-inflammatory, immunosuppressive, and analgesic properties. Its mechanisms of action include modulation of immune pathways such as Th17 cell differentiation and C-type lectin receptor signaling; inhibition of the PI3K/AKT pathway via upregulation of PTEN; suppression of CD36 expression; activation of AMPK signaling; promotion of autophagy; and inhibition of apoptosis in renal tissues. Clinical studies have shown that CRT significantly reduces proteinuria in patients with chronic glomerulopathy (including IgA nephropathy, membranous nephropathy, and diabetic kidney disease), with a favorable safety profile[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colquhounia root tablet.